Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

" then "Webcast." The conference call will be archived and available to investors for one week after the call.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: AMRIX, TREANDA, FENTORA(R) (fentanyl buccal tablet) [C-II], PROVIGIL(R) (modafinil) Tablets [C-IV], TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; characterization
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... flooding that devastated a wide swath of Colorado last ... roads and other infrastructure had been upgraded or modernized, ... Colorado Denver. , "People need to understand the importance ... professor of structural engineering at the CU Denver College ... study. "There is an assumption that a bridge will ...
(Date:10/27/2014)... , October 27, 2014 ... to produce, exhibit and sell its artificial "lower ... impeach their patent.      (Photo: ... years of fighting, the definitive judgement has arrived: ... produces innovative and accessible hi-tech prostheses with composite ...
(Date:10/27/2014)... The “Molecular Diagnostic Market ... (PCR, INAAT, DNA Sequencing), End User (Hospital, Laboratories), ... Global Forecast to 2018” provides a detailed overview ... market trends, and strategies impacting the global molecular ... of the revenue and share analysis. , The ...
(Date:10/27/2014)... The report “Smart Highway Market by ... Monitoring), and by Display (Variable Message Signs, Digital ... global market into various sub-segments with in-depth analysis ... drivers and restraints for this market with insights ... market tables and 37 figures spread through 141 ...
Breaking Biology Technology:CU Denver study says upgrading infrastructure could reduce flood damage 2Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4
... , GUNMA, Japan and ATLANTA , May 17 ... Electric Corporation came to fruition in March when Gunma University Heavy Ion ... cancer. Elekta and Mitsubishi Electric worked to facilitate the use of Elekta,s ... beam treatment system. , , ...
... Latest Biomedical Licensing Opportunities , ... KANSAS CITY, Mo. , May 17 ... Innovation Network, Inc., today announced that it is continuing its strategic ... (UHN), a group of leading research hospitals and institutes based in ...
... YORK , May 17 /PRNewswire-Asia/ -- Tiens Biotech Group ( USA ), Inc. (the,"Company" or ... ended March 31, 2010 . , , , ... quarter of 2010 was $11.4 million , compared to $18.2,million for the first quarter ... Net income for the first quarter of 2010 ...
Cached Biology Technology:Elekta / Mitsubishi Electric Collaboration Helps Japan's Gunma University Heavy Ion Medical Center Launch Advanced Carbon Ion Therapy for Treating Cancer 2The iBridge Network Adds Toronto's University Health Network as First Canadian Partner 2The iBridge Network Adds Toronto's University Health Network as First Canadian Partner 3Tiens Biotech Group (USA) Reports First Quarter Results 2Tiens Biotech Group (USA) Reports First Quarter Results 3Tiens Biotech Group (USA) Reports First Quarter Results 4Tiens Biotech Group (USA) Reports First Quarter Results 5Tiens Biotech Group (USA) Reports First Quarter Results 6Tiens Biotech Group (USA) Reports First Quarter Results 7Tiens Biotech Group (USA) Reports First Quarter Results 8Tiens Biotech Group (USA) Reports First Quarter Results 9Tiens Biotech Group (USA) Reports First Quarter Results 10Tiens Biotech Group (USA) Reports First Quarter Results 11
(Date:10/29/2014)... EAST LANSING, Mich. – As bodies decompose, their ... Deciphering the clues they provide could mean the ... murder. , Michigan State University is using a ... to help Detroit death-scene investigators examine these changing ... such as geographical location of death, gender, race, ...
(Date:10/29/2014)... reveals new research potential of the Barcode of ... in the Biodiversity Data Journal ... format and imported these into a human-readable text developed ... (PWT). Data were used to study the species distributions ... Microgastrinae subfamily. , BOLD is originally designed to support ...
(Date:10/29/2014)... a hormone released by the stomach and it stimulates ... a psychoactive substance that primarily affects brain function, but ... This knowledge, combined with findings from animal studies, led ... to stimulate alcohol craving. , Dr. Lorenzo Leggio and ... as they had anticipated, alcohol craving was increased in ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Ghrelin stimulates an appetite for drinking alcohol 2
... SASKATCHEWAN Canadian Light Source (CLS) staff scientist Luca Quaroni ... Surgery at the University of Saskatchewan (U of S) ... with a condition known as Barrett,s Esophagus from chemical ... esophageal cancer. The finding is published in the June, ...
... French . Toronto (June 5, 2009) - ... announce another measure to address the H1N1 flu virus. The ... focused on pandemic vaccine evaluation. The network will strengthen Canada,s ... influenza vaccine and vaccination programs. The network was created ...
... Australia have presented a Canadian-based UN coral reef specialist ... in marine research. Peter Sale, Assistant Director for ... on Water, Environment and Health, and Emeritus Professor at ... for Excellence in Indo-Pacific ichthyology at the 8th Indo-Pacific ...
Cached Biology News:University of Saskatchewan and Canadian Synchrotron researchers shed light on esophageal disease 2Government of Canada announces funding for research on the H1N1 flu virus 2Canadian-based UN coral reef expert honored at world meeting in Australia 2
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
EDTA, disodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99.0-101.0%, nuclease-free.Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemi...
Alkaline Phosphatase Stabilizer Solution, 1 L...
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5...
Biology Products: